Stockreport

ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

ReShape Lifesciences, Inc.  (RSLS) 
US:NASDAQ Investor Relations: ir.enteromedics.com
PDF Significant Reduction in Overall Operating Expenses of 45.4% in the First Half of 2024 Compared to the First Half of 2023 Conference Call to be Held at 4:30 pm ET on [Read more]